PET imaging can reassure previously treated women they are breast cancer free, and can better predict if their disease is likely to recur than other types of diagnostic imaging, according to researchers.
The study, published in the March issue of The Journal of Nuclear Medicine, compared the outcomes of 61 women previously treated for breast cancer. The women received both 18F-FDG PET and conventional imaging (CI), and were followed-up for at least 6 months to determine how, or if, their disease progressed.
Significantly, all six women with positive CI results, indicating their disease had returned, but whose PET scans were negative, were free of disease at last follow-up. In the nine women with negative CI but positive PET results, six were later found to have recurrent disease and received additional treatment. Overall, PET and CI findings differed in a quarter of the women; PET correctly predicted the outcome in 80% of these cases vs. 20% for CI.
PET was also better at determining the length of disease-free survival, with 90% accuracy vs. 75% for CI. Women with positive results for both PET and CI showed similar periods of survival; however, women with negative PET results had significantly longer disease-free survival than those with negative CI results. Overall, PET demonstrated better sensitivity (93% v. 79%) and specificity (84% v. 68%) than CI. CI includes imaging techniques such as x-ray, CT, sonography, MRI, mammography, and bone scans.
The authors point out that early detection of local recurrence and metastatic disease can impact therapy. For example, local recurrence and axillary lymph node involvement may be treated surgically or with radiation, whereas mediastinal lymph node involvement or distant metastases typically require chemotherapy. The six women with true-positive PET results and false-negative CI were able to receive treatment for their recurrence, such as additional chemotherapy, radiation, and surgery.
However, at the end of follow-up, all six women had evidence of disease. The authors concluded that although earlier detection did not result in remission in these cases, it might have delayed the progression of disease.
According to the American Cancer Society approximately 203,500 women will be diagnosed with breast cancer this year. The Center for Medicare and Medicaid Services (CMS) decided on February 27 to reimburse for FDG PET scans for staging patients with distant metastasis or for restaging patients with locoregional recurrence or metastasis, and to determine how patients are responding to treatment.
Whole-Body 18F-Fdg PET and Conventional Imaging for Predicting Outcome in Previously Treated Breast Cancer Patients was prepared by Duska Vranjesevic, MD; Jean Emmanuel Filmont, MD; Joubin Meta, MS; Daniel H. Silverman, MD, PhD; and Michael E. Phelps, PhD, of the Department of Nuclear Medicine, UCLA School of Medicine, Los Angeles, California; Peter E. Valk, MD, of the Northern California PET Imaging Center, Sacramento, California; and Johannes Czernin, MD, of the Department of Nuclear Medicine, UCLA School of Medicine, Los Angeles, California.
The above post is reprinted from materials provided by Society Of Nuclear Medicine. Note: Materials may be edited for content and length.
Cite This Page: